Skip Navigation LinksHome > September 2012 - Volume 31 - Issue 9 > Topical Autologous Platelet-Rich Plasma Eyedrops for Acute C...
Cornea:
doi: 10.1097/ICO.0b013e3182114661
Clinical Science

Topical Autologous Platelet-Rich Plasma Eyedrops for Acute Corneal Chemical Injury

Panda, Anita MD, FAMS, FICP, MRCOphth*; Jain, Mohit MD*; Vanathi, Murugesan MD*; Velpandian, Thurimurthy MD; Khokhar, Sudarshan MD*; Dada, Tanuj MD*

Collapse Box

Abstract

Purpose: Evaluation of efficacy of autologous platelet-rich plasma eyedrops as an adjunct to standard medical treatment as compared with standard medical treatment with artificial tears in acute ocular chemical injury.

Methods: Twenty eyes with grade III to grade V chemical injury were randomly assigned to 2 groups. Group I (10 eyes) received autologous platelet-rich plasma eyedrops along with standard medical treatment, and group II (10 eyes) received standard medical treatment alone. Follow-up was on days 3, 7, 14, 21, 30, 60, and 90. Chi-square test for categorical variables and Mann–Whitney test for quantitative variables were applied for statistical analysis.

Results: The mean time between exposure and presentation was 2.15 ± 0.93 days (group I, 2.2 ± 0.73 days; group II, 2.1 ± 0.98 days; P = 0.81). Complete epithelialization was achieved in all the eyes. The mean ± SD and median (range) time to complete epithelialization were 40 ± 31.57 days and 25.5 (7–90) days in group I and 47 ± 26.15 days and 30.0 (21–90) days in group II (P = 0.29). For grade III injuries, mean ± SD and median (range) time to complete epithelialization were 14 ± 7 days and 14 (7–21) days in group I and 28.5 ± 3.67 days and 28.5 (21–30) days in group II (P = 0.006) [Wilcoxon rank sum (Mann–Whitney) test]. At 3 months, corneal clarity showed significant improvement in grade I compared with grade II (P = 0.048). Similarly, the percentage improvement in best-corrected visual acuity was 63.64 ± 55.75 and 37.74 ± 9.66 for grades I and II, respectively (P = 0.082).

Conclusions: Topical autologous platelet-rich plasma therapy is safe and effective, and it promotes rapid reepithelialization of ocular surface and can be administered along with standard medical therapy.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.